IRCT20200407046981N28尚未招募未知
Comparative bioequivalence study of Gemfibrozil 300-mg capsules manufactured by Daana Pharmaceutical Company versus Lopid® (Pfizer)
Daana pharmaceutical company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Gemfibrozil or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
已完成
1 期
Bioequivalence Study Between Two Oral Formulations of Gemfibrozil TabletsBioavailabilityNCT00800475Blu Caribe40
招募中
3 期
Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorderMajor Depressive Disorder.Major depressive disorder, single episode, severe without psychotic featuresF32.2IRCT20090117001556N119Tehran University of Medical Sciences40
尚未招募
不适用
Comparative in vivo evaluation of 2 Glibenclamide 5 mg Tablet formulations.Diabetes Mellitus.Type 2 diabetes mellitusIRCT20180620040164N32Dorsa Pharmaceutical Co.24
已完成
1 期
To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656Type 2 Diabetes MellitusNCT01083212AstraZeneca19
招募中
3 期
Efficacy of Gemfibrozil as an adjust therapy in obsessive compulsive disorder, a randomized clinical trial with medication controlObsessives-Compulsive disorder.Obsessive-compulsive personality disorderF60.5IRCT20230211057389N1Karaj University of Medical Sciences40